Ono Pharmaceutical Co. Ltd

Pharma

Osaka, Japan, Japan · Est. 1717 · 12,000 employees

Ono Pharmaceutical is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in oncology, immunology, and other therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

109

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

14 drugs in development

Phase 34

Phase 27

Phase 19

By Therapeutic Area

top 6

Oncology

947%

Immunology

211%

Psychiatry

211%

Neurology

211%

Hematology

15%

Musculoskeletal

15%

R&D Momentum

60/100

Pipeline Velocity

22/100

Trial Completion Rate

91/100

Pipeline Concentration

27/100

Pipeline Freshness

69/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Recruiting

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma

Jul 9, 2026

Recruiting

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Jul 9, 2026

Completed

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Major Depressive Disorder

Jul 9, 2026

Completed

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Social Anxiety Disorder

Jul 8, 2026

Completed

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Fibromyalgia

Jul 8, 2026

Completed

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

Earlier

Jun 30, 2026TrialA Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy

Jun 27, 2026TrialA Phase 1, Open-Label, Parallel-Group Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

4 more events

Jun 26, 2026TrialA Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as "Chemotherapy") Versus Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Nov 19, 2025TrialONO-4538 Study in Patients With Richter's Transformation

Nov 18, 2025TrialA Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

May 1, 2025TrialA Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

Details

Company Info

Company Overview

$8.5B

Mkt Cap

$4.5B

Revenue

—

Cash

CEOGenta Nakamura

Founded1717

Employees12,000

HQOsaka, Japan, Japan

Websiteono.co.jp/en/

LinkedInCompany Page

Therapeutic Focus

OncologyImmunologyCardiovascular

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dermatology(1 drug)

—

Dermatology(1 drug)

Hematology(1 drug)

—

Hematology(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(9 drugs)

—

Oncology(9 drugs)

Psychiatry(2 drugs)

—

Psychiatry(2 drugs)

Unknown / Other(1 drug)

—

Unknown / Other(1 drug)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)